PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

MinervaX reveals completion of vaccine trial enrolment

The company is seeking to address the worldwide impact of group B streptococcus in older adults.

MinervaX – a company developing a prophylactic vaccine against group B streptococcus (GBS) – has announced the completion of enrolment and initial dosing for its phase 1, clinical vaccine trial among older adults.

The trial is taking place at CEVAC (Centre for Vaccinology) in Belgium. GBS is most commonly linked with pregnant women and newborn babies, however, invasive GBS disease infections in the elderly population are rapidly increasing.

The condition can have very serious consequences – particularly if the individual already has another health condition such as cancer, diabetes mellitus, or a suppressed immune system.

In order to address the problem, MinervaX has widened the development pipeline of its novel GBS vaccine to include older adults, with the aim of preventing and reducing deaths associated with GBS across international communities

At present, MinervaX is progressing two phase 2 clinical vaccine trials for the prevention of life-threatening infections among newborns. The trials are showing that the vaccine has a sound safety profile, is significantly immunogenic and encourages functionally active antibodies.

The phase 1 vaccine trial is researching the vaccine’s safety and immunogenicity in both healthy older adults and older adults with underlying medical conditions, at an age range of 55 to 75 years and incorporating a range of dose levels.

Professor Isabel Leroux-Roels, the principal investigator at CEVAC, reflected: “We at CEVAC are very pleased to be contributing to this phase 1 trial against this severe disease. Recruiting the many volunteers for this hugely important trial is a step forward to demonstrate that MinervaX’s novel vaccine works.”

She added: “We are very grateful to all the volunteers involved in the trial and will be following up with each participant accordingly. We are excited to see the data reported later this year.”

Lidia Oostvogels, chief medical officer of MinervaX, concluded: “The smooth completion of enrolment and dose escalation provides an indication of the overall acceptable reactogenicity profile of our novel GBS vaccine and replicates the findings in our two ongoing phase 2 trials in pregnant women.

“This allows us to accelerate the development of this potentially lifesaving vaccine to address the global unmet medical need. I would like to thank the participants of the trial and the team at CEVAC who is being instrumental throughout the trial, and I look forward to providing initial results in the fourth quarter of 2023.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026